NCT06232408View on ClinicalTrials.gov

LIONS (PLK4 Inhibitor in Advanced Solid Tumors)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

RP-1664

RP-1664 will be supplied as immediate-release solid dosage form for oral self-administration.

Trial Locations (5)

10032

Participating Site 1008, New York

10065

Participating Site 1004, New York

94143

Participating Site 1025, San Francisco

06519

Participating Site 1012, New Haven

Unknown

Participating Site 4001, Copenhagen

Sponsors
All Listed Sponsors
lead

Repare Therapeutics

INDUSTRY

NCT06232408 - LIONS (PLK4 Inhibitor in Advanced Solid Tumors) | Biotech Hunter | Biotech Hunter